what are the side effects of semaglutide injection GLP-1 and Semaglutide: Why Smart Biomarker Monitoring Matters Semaglutide & Gut Health: Surprising

Q2 2025 Snapshot Eli Lilly and Company dominates the US 57 % GLP-1 share, led by Mounjaro (tirzepatide) HCP & Zepbound (tirzepatide) HCP Novo Nordisk rules Europe 63 % value share, powered by Wegovy(semaglutide) injection 2.4 mg HCP & Ozempic APAC & Emerging Markets are the next frontier (+1113 % YoY) Together, they crossed $24 Billion in H1 2025 GLP-1 revenue proving the real blockbuster of this decade isnt oncology or immunology Its metabolic health

Take home message You can take Wegovy if you have gallstones, but you should work with your doctor to develop a monitoring plan and take precautions to minimise risks

We are advocating within Canada for coverage of these

Proc Natl Acad Sci U S A 102:565570